Management of acquired von Willebrand's syndrome in a patient requiring major surgery

Haemophilia

Volumn 11, Issue 6, 2005, Pages 633-637

  Maddox, Jamie M ^a   Anderson, J A M ^b   Plews, D ^c   Ludlam, C A ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b HAMILTON GENERAL HOSPITAL   (Canada)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Acquired von Willebrand's syndrome; Intravenous immunoglobulin; Management; Plasma exchange

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BCG VACCINE; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; IMMUNOGLOBULIN G; TINZAPARIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

ADJUVANT THERAPY; AGED; ARTICLE; BLADDER CARCINOMA; BLEEDING; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CASE REPORT; CYSTECTOMY; DISEASE COURSE; DRUG CLEARANCE; DRUG COMPETITION; DRUG HALF LIFE; HEMATURIA; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; NOCTURIA; PERIOPERATIVE PERIOD; PLASMAPHERESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEPTICEMIA; STAPHYLOCOCCUS AUREUS; THROMBOSIS; TRANSITIONAL CELL CARCINOMA; VON WILLEBRAND DISEASE;

BLOOD LOSS, SURGICAL; CARCINOMA, TRANSITIONAL CELL; FACTOR VIII; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMA EXCHANGE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 27744434517     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01150.x     Document Type: Article

References (19)

1. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Shroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001; 14: 401-36.
2. Federici AB, Rand JH, Bucciarelli P et al. Acquired von Willebrand syndrome: data from an International Registry. Thromb Haemost 2000; 84: 345-9.
3. Federici AB. Therapeutic approaches to acquired von Willebrand syndrome. Expert Opin Investig Drugs 2000; 9: 347-54.
4. Silberstein LE, Abrahm J, Shattil SJ. The efficacy of intensive plasma exchange in acquired von Willebrand's disease. Transfusion 1987; 27: 234-7.
5. Bovill EG, Ershler WB, Golden EA, Tindle BH, Edson JR. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986; 85: 115-23.
6. Hayashi T, Yagi H, Suzuki H et al. Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance. Pathophysiol Haemost Thromb 2002; 32: 33-9.
7. Frank RD, Kunz D, Wirtz DC. Willebrand disease-hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin and continuous factor concentrate infusion. Am J Hematol 2002; 70: 64-71.
8. Michiels JJ, van Vliet HH. Willebrand disease in monoclonal gammopathies: effectiveness of high-dose intravenous immunoglobulin. Clin Appl Thromb Hemost 1999; 5: 152-7.
9. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92: 2707-11.
10. Van Genderen PJ, Michiels JJ, Bakker JJ, van't Veer MB. Effectiveness of high-dose gamma globulin therapy in acquired von Willebrand's disease. Vox Sang 1994; 67: 14-7.
11. Castaman G, Tosetto A, Rodeghiero F. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VII concentrate. Am J Hematol 1992; 41: 132-6.
12. Delannoy A, Saillez AC. High-dose intravenous gammaglobulin for acquired von Willebrand's disease. Br J Haematol 1988; 70: 387.
13. Arkel YS, Lynch J, Kamiyama M. Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin. Thromb Haemost 1994; 72: 643-4.
14. Hanley D, Arkel YS, Lynch J, Kamiyama M. Willebrand's syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin. Am J Hematol 1994; 46: 141-6.
15. Delmer A, Horellou MH, Brechot JM et al. Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins. Am J Hematol 1992; 40: 151-2.
16. Macik BG, Gabriel DA, White GC II, High K, Roberts H. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome. Arch Pathol Lab Med 1988; 112: 143-6.
17. Mohri H, Motomura S, Kanamori H et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-9.
18. Smaradottir A, Bona R. A case of acquired von Willebrand syndrome successfully treated with recombinant factor VIIa during thyroidectomy. Thromb Haemost 2005; 93: 1009.
19. Friedrich PW, Wever PC, Briet E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66: 292-4.